Francis Medical designed its Vanquish system with needle guidance and hands-free stabilization for vapor ablation of the ...

Francis Medical is heating up with a 510 (k) clearance from the FDA for its water vapor ablation therapy aimed at cancers of ...

Francis Medical has received FDA clearance for its Vanquish water vapor ablation system for the management of prostate cancer ...

Investigators reported an 88% early treatment success rate in 52 men who underwent MRI-guided transurethral ultrasound ablation for localized prostate cancer. Customized prostate ablation with ...

Research published in The Journal of Urology offers an alternative to invasive prostate cancer treatments like surgery and radiation. Standard treatments can have serious side effects such as urinary ...

Francis Medical has obtained $80 million in venture capital funding to support the development of its water vapor ablation therapy for cancers of the prostate, kidneys and bladder. The series C round ...

Enzyme ablation of the hyperplastic prostate may be an ideal method of management of BPH. However, the unsatisfactory ablation affects in vivo contrast with successful in vitro results limiting the ...

Prostate cancer may soon be treated more effectively using ultrasound at therapeutic levels, without the significant and distressing side effects of more traditional treatments. A new study presented ...

Background: Androgen ablation is often used in addition to low-dose-rate brachytherapy in the treatment of prostate cancer, particularly for disease with adverse features. We report a ...

Prostate cancers are either low-grade, low-risk forms that may be monitored but otherwise untreated, or they’re serious enough to require surgery and radiation. Monitoring can cause patients anxiety.

Up until now, capturing an image of a prostate cancer has been difficult because prostate tissue and tumor tissue are so similar. Precise, non-invasive surgical treatment has proved difficult as a ...

Focal laser ablation (FLA) for prostate cancer shows "promising early oncologic results" and "acceptable morbidity" in men with low- to intermediate-risk prostate cancer, concludes a new single-center ...